DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financi...((R) Product Revenues: United State...),Health

Date:8/11/2009

(R) Product Revenues: United States $5,621,000 $4,572,000 $11,306,000 $9,346,000 Canada 108,000 218,000 243,000 377,000 Korea 126,000 159,000 296,000 524,000 Other 84,000 133,000 171,000 190,000 ------ ------- ------- ------- Subtotal Kerastick(R) Product Revenues 5,939,000 5,082,000 12,016,000 10,437,000 BLU-U(R) Product Revenues: United States 479,000 347,000 1,121,000 822,000 ------- ------- --------- ------- Subtotal BLU-U(R) Product Revenues 479,000 347,000 1,121,000 822,000 Total PDT Drug & Device Product Revenues 6,418,000 5,429,000 13,137,000 11,259,000 Total Non-PDT Product Revenues 548,000 2,683,000 967,000 4,783,000 ------- --------- ------- --------- TOTAL PRODUCT REVENUES $6,966,000 $8,112,000 $14,104,000 $16,042,000 ========== ========== =========== ===========

    DUSA Pharmaceuticals, Inc.
    Condensed Consolidated Balance Sheets

                                          June 30,      December 31,
                                             2009           2008
                                          (Unaudited)
                                          -----------    -----------

    ASSETS
    CURRENT ASSETS
      Cash and cash equivalents            $3,894,037     $3,880,673
      Marketable securities                12,488,406     15,002,830
      Accrued interest receivable             144,523        155,728
      Accounts receivable, net              1,550,149      2,367,803
      Inventory                     
'/>"/>
SOURCE  DUSA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 
Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals